Novel low-avidity CAR-Ts for liver cancer

Industry: Liver cancer therapeutics

Liver cancer is responsible for the third-highest deaths from cancer per year, and it has proven resistant to leading treatments such as CAR-T (chimeric antigen receptor) therapy, which induces the body’s T cells to fight cancer cells. 

The Novel Low-Avidity CAR-T project has developed a novel CAR-T method that allows the T cells to function persistently inside of solid tumors without becoming exhausted.

The incidence rate of liver cancer in the USA doubled between 1999 and 2016, highlighting the need for new and effective therapies.

Back to companies